Standard

Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability. / Iyevleva, Aglaya G; Aleksakhina, Svetlana N; Sokolenko, Anna P; Baskina, Sofia V; Venina, Aigul R; Anisimova, Elena I; Bizin, Ilya V; Ivantsov, Alexandr O; Belysheva, Yana V; Chernyakova, Alexandra P; Togo, Alexandr V; Imyanitov, Evgeny N.

в: Breast Cancer Research and Treatment, Том 192, № 2, 04.2022, стр. 283-291.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Iyevleva, AG, Aleksakhina, SN, Sokolenko, AP, Baskina, SV, Venina, AR, Anisimova, EI, Bizin, IV, Ivantsov, AO, Belysheva, YV, Chernyakova, AP, Togo, AV & Imyanitov, EN 2022, 'Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability', Breast Cancer Research and Treatment, Том. 192, № 2, стр. 283-291. https://doi.org/10.1007/s10549-022-06517-3

APA

Iyevleva, A. G., Aleksakhina, S. N., Sokolenko, A. P., Baskina, S. V., Venina, A. R., Anisimova, E. I., Bizin, I. V., Ivantsov, A. O., Belysheva, Y. V., Chernyakova, A. P., Togo, A. V., & Imyanitov, E. N. (2022). Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability. Breast Cancer Research and Treatment, 192(2), 283-291. https://doi.org/10.1007/s10549-022-06517-3

Vancouver

Author

Iyevleva, Aglaya G ; Aleksakhina, Svetlana N ; Sokolenko, Anna P ; Baskina, Sofia V ; Venina, Aigul R ; Anisimova, Elena I ; Bizin, Ilya V ; Ivantsov, Alexandr O ; Belysheva, Yana V ; Chernyakova, Alexandra P ; Togo, Alexandr V ; Imyanitov, Evgeny N. / Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability. в: Breast Cancer Research and Treatment. 2022 ; Том 192, № 2. стр. 283-291.

BibTeX

@article{3c63cb1e783a4f22946c2dbc3e2b420b,
title = "Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability",
abstract = "PURPOSE: Germline mutations in CHEK2 gene represent the second most frequent cause of hereditary breast cancer (BC) after BRCA1/2 lesions. This study aimed to identify the molecular characteristics of CHEK2-driven BCs.METHODS: Loss of heterozygosity (LOH) for the remaining CHEK2 allele was examined in 50 CHEK2-driven BCs using allele-specific PCR assays for the germline mutations and analysis of surrounding single-nucleotide polymorphisms (SNPs). Paired tumor and normal DNA samples from 25 cases were subjected to next-generation sequencing analysis.RESULTS: CHEK2 LOH was detected in 28/50 (56%) BCs. LOH involved the wild-type allele in 24 BCs, mutant CHEK2 copy was deleted in 3 carcinomas, while in one case the origin of the deleted allele could not be identified. Somatic PIK3CA and TP53 mutations were present in 13/25 (52%) and 4/25 (16%) tumors, respectively. Genomic features of homologous recombination deficiency (HRD), including the HRD score ≥ 42, the predominance of BRCA-related mutational signature 3, and the high proportion of long (≥ 5 bp) indels, were observed only in 1/20 (5%) BC analyzed for chromosomal instability. Tumors with the deleted wild-type CHEK2 allele differed from LOH-negative cases by elevated HRD scores (median 23 vs. 7, p = 0.010) and higher numbers of chromosomal segments affected by copy number aberrations (p = 0.008).CONCLUSION: Somatic loss of the wild-type CHEK2 allele is observed in approximately half of CHEK2-driven BCs. Tumors without CHEK2 LOH are chromosomally stable. BCs with LOH demonstrate some signs of chromosomal instability; however, its degree is significantly lower as compared to BRCA1/2-associated cancers.",
keywords = "CHEK2 mutation, Hereditary breast cancer, Homologous recombination deficiency, Loss of heterozygosity, CHEK2-ASTERISK-1100DELC, 1100DELC, TUMOR CHARACTERISTICS, WOMEN, REPAIR, GENE, INCREASED RISK, CHEK2, MUTATION, RESISTANT PROSTATE-CANCER, Checkpoint Kinase 2/genetics, Humans, Loss of Heterozygosity, Alleles, Germ-Line Mutation, Female, Breast Neoplasms/genetics, Chromosomal Instability",
author = "Iyevleva, {Aglaya G} and Aleksakhina, {Svetlana N} and Sokolenko, {Anna P} and Baskina, {Sofia V} and Venina, {Aigul R} and Anisimova, {Elena I} and Bizin, {Ilya V} and Ivantsov, {Alexandr O} and Belysheva, {Yana V} and Chernyakova, {Alexandra P} and Togo, {Alexandr V} and Imyanitov, {Evgeny N}",
note = "Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2022",
month = apr,
doi = "10.1007/s10549-022-06517-3",
language = "English",
volume = "192",
pages = "283--291",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer Nature",
number = "2",

}

RIS

TY - JOUR

T1 - Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability

AU - Iyevleva, Aglaya G

AU - Aleksakhina, Svetlana N

AU - Sokolenko, Anna P

AU - Baskina, Sofia V

AU - Venina, Aigul R

AU - Anisimova, Elena I

AU - Bizin, Ilya V

AU - Ivantsov, Alexandr O

AU - Belysheva, Yana V

AU - Chernyakova, Alexandra P

AU - Togo, Alexandr V

AU - Imyanitov, Evgeny N

N1 - Publisher Copyright: © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

PY - 2022/4

Y1 - 2022/4

N2 - PURPOSE: Germline mutations in CHEK2 gene represent the second most frequent cause of hereditary breast cancer (BC) after BRCA1/2 lesions. This study aimed to identify the molecular characteristics of CHEK2-driven BCs.METHODS: Loss of heterozygosity (LOH) for the remaining CHEK2 allele was examined in 50 CHEK2-driven BCs using allele-specific PCR assays for the germline mutations and analysis of surrounding single-nucleotide polymorphisms (SNPs). Paired tumor and normal DNA samples from 25 cases were subjected to next-generation sequencing analysis.RESULTS: CHEK2 LOH was detected in 28/50 (56%) BCs. LOH involved the wild-type allele in 24 BCs, mutant CHEK2 copy was deleted in 3 carcinomas, while in one case the origin of the deleted allele could not be identified. Somatic PIK3CA and TP53 mutations were present in 13/25 (52%) and 4/25 (16%) tumors, respectively. Genomic features of homologous recombination deficiency (HRD), including the HRD score ≥ 42, the predominance of BRCA-related mutational signature 3, and the high proportion of long (≥ 5 bp) indels, were observed only in 1/20 (5%) BC analyzed for chromosomal instability. Tumors with the deleted wild-type CHEK2 allele differed from LOH-negative cases by elevated HRD scores (median 23 vs. 7, p = 0.010) and higher numbers of chromosomal segments affected by copy number aberrations (p = 0.008).CONCLUSION: Somatic loss of the wild-type CHEK2 allele is observed in approximately half of CHEK2-driven BCs. Tumors without CHEK2 LOH are chromosomally stable. BCs with LOH demonstrate some signs of chromosomal instability; however, its degree is significantly lower as compared to BRCA1/2-associated cancers.

AB - PURPOSE: Germline mutations in CHEK2 gene represent the second most frequent cause of hereditary breast cancer (BC) after BRCA1/2 lesions. This study aimed to identify the molecular characteristics of CHEK2-driven BCs.METHODS: Loss of heterozygosity (LOH) for the remaining CHEK2 allele was examined in 50 CHEK2-driven BCs using allele-specific PCR assays for the germline mutations and analysis of surrounding single-nucleotide polymorphisms (SNPs). Paired tumor and normal DNA samples from 25 cases were subjected to next-generation sequencing analysis.RESULTS: CHEK2 LOH was detected in 28/50 (56%) BCs. LOH involved the wild-type allele in 24 BCs, mutant CHEK2 copy was deleted in 3 carcinomas, while in one case the origin of the deleted allele could not be identified. Somatic PIK3CA and TP53 mutations were present in 13/25 (52%) and 4/25 (16%) tumors, respectively. Genomic features of homologous recombination deficiency (HRD), including the HRD score ≥ 42, the predominance of BRCA-related mutational signature 3, and the high proportion of long (≥ 5 bp) indels, were observed only in 1/20 (5%) BC analyzed for chromosomal instability. Tumors with the deleted wild-type CHEK2 allele differed from LOH-negative cases by elevated HRD scores (median 23 vs. 7, p = 0.010) and higher numbers of chromosomal segments affected by copy number aberrations (p = 0.008).CONCLUSION: Somatic loss of the wild-type CHEK2 allele is observed in approximately half of CHEK2-driven BCs. Tumors without CHEK2 LOH are chromosomally stable. BCs with LOH demonstrate some signs of chromosomal instability; however, its degree is significantly lower as compared to BRCA1/2-associated cancers.

KW - CHEK2 mutation

KW - Hereditary breast cancer

KW - Homologous recombination deficiency

KW - Loss of heterozygosity

KW - CHEK2-ASTERISK-1100DELC

KW - 1100DELC

KW - TUMOR CHARACTERISTICS

KW - WOMEN

KW - REPAIR

KW - GENE

KW - INCREASED RISK

KW - CHEK2

KW - MUTATION

KW - RESISTANT PROSTATE-CANCER

KW - Checkpoint Kinase 2/genetics

KW - Humans

KW - Loss of Heterozygosity

KW - Alleles

KW - Germ-Line Mutation

KW - Female

KW - Breast Neoplasms/genetics

KW - Chromosomal Instability

UR - https://proxy.library.spbu.ru:2096/article/10.1007%2Fs10549-022-06517-3#citeas

UR - http://www.scopus.com/inward/record.url?scp=85122744604&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/5bcaab9c-7c10-3395-a447-9b0d0e53ea4d/

U2 - 10.1007/s10549-022-06517-3

DO - 10.1007/s10549-022-06517-3

M3 - Article

C2 - 35020107

VL - 192

SP - 283

EP - 291

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -

ID: 91805277